Advertisement
UK markets close in 7 hours 18 minutes

  • FTSE 100

    8,281.53
    +68.04 (+0.83%)
     

  • FTSE 250

    20,353.36
    +188.82 (+0.94%)
     

  • AIM

    776.54
    +5.01 (+0.65%)
     

  • GBP/EUR

    1.1651
    -0.0009 (-0.08%)
     

  • GBP/USD

    1.2537
    -0.0026 (-0.21%)
     

  • Bitcoin GBP

    50,781.66
    -728.23 (-1.41%)
     

  • CMC Crypto 200

    1,369.44
    +4.32 (+0.32%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • DOW

    38,852.27
    +176.59 (+0.46%)
     

  • CRUDE OIL

    78.51
    +0.03 (+0.04%)
     

  • GOLD FUTURES

    2,327.30
    -3.90 (-0.17%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,474.29
    -104.01 (-0.56%)
     

  • DAX

    18,227.80
    +52.59 (+0.29%)
     

  • CAC 40

    8,015.13
    +18.49 (+0.23%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

BUZZ-Top of the Street: Aggreko, Rubis, SGS, Eurofins

Reuters - UK Focus

A round-up of notable broker activity this morning from Europe's top-ranked* analysts:

** Credit Suisse (IOB: 0QP5.IL - news) upgrades Aggreko (Frankfurt: A1XFZR - news) to "neutral" on valuation grounds

** Berenberg downgrades Rubis (LSE: 0MUI.L - news) to "hold", says weakness in storage business in Q1 2018 is likely to persist in short- to medium-term

** Barclays (LSE: BARC.L - news) upgrades SGS (LSE: 0QMI.L - news) to "overweight", due to accelerating organic growth and recovery in oil & gas minerals industries

** Jefferies upgrades Eurofins Scientific (Hamburg: 719177.HM - news) to "buy" after co upgrades its revenue guidance

ADVERTISEMENT

** Goldman Sachs (NYSE: GS-PB - news) reinstates Inmarsat (Other OTC: IMASF - news) and Eutelsat (Paris: FR0010221234 - news) with "neutral"

(*Analyst rankings from Thomson Reuters StarMine. Scale is from 1-star to 5-star with 5 being best. Analysts ranked on earnings accuracy as well as relative performance of recommendations over trailing 12-month & 24-month periods.)